MedTrace Logo

An Open Trial to Assess the Tolerability of AVANZ® Cupressus Immunotherapy

NCT02069535 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2015-01-06

No results posted yet for this study

Summary

This trial is an open, national, multi-centre trial. The main objective of this trial is to assess the tolerability of the up-dosing phase of AVANZ® Cupressus arizonica by measurement of related Adverse Events.

Conditions

  • Allergic Rhinoconjunctivitis

Interventions

BIOLOGICAL

AVANZ Cupressus

AVANZ Cupressus

Sponsors & Collaborators

  • ALK-Abelló A/S

    lead INDUSTRY

Principal Investigators

  • Montserrat Fernández Rivas, PhD · Hospital Clínico Universitario San Carlos, Madrid

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-04-30
Primary Completion
2014-11-30
Completion
2014-11-30

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02069535 on ClinicalTrials.gov